Johnson & Johnson reported a $7 billion charge in third quarter 2026 earnings, resulting in a 96 percent decline in GAAP earnings per share. Despite this hit, the company raised its full-year revenue and earnings guidance.
The charge breaks into two parts: a $5.5 billion proposed settlement of talc litigation and expenses tied to strategic acquisitions, including Firefly Bio and a Sail Biomedicines partnership.
J&J previously spun off its talcum powder business but continues to face cancer allegations related to talc products. The settlement structure includes a $3 billion payment due in 2027, with the remainder paid over subsequent years. Management views the resolution as strategically necessary—addressing a legal drag that has weighed on operations and brand perception for years.
Core business strength justified the raised guidance. Revenues grew nearly 6 percent in the quarter, demonstrating underlying resilience independent of one-time charges.
J&J maintains its status as a Dividend King with 64 consecutive annual increases—the longest streak in healthcare. The company's ability to fund both a major legal settlement and strategic growth investments while sustaining that dividend speaks to durable free cash flow generation.
For equity investors, the key takeaway is this: J&J is choosing to clean up legacy liabilities now, during a period of economic strength, to unlock focus on high-growth initiatives. The raised guidance suggests management confidence that core operations can absorb the charge without impacting medium-term earnings power. Watch next quarter's revenue growth trajectory and free cash flow conversion to confirm the company can sustain both its dividend and reinvestment pace.
